Lai-Fong Poon
Overview
Explore the profile of Lai-Fong Poon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
222
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ooi W, Xing M, Xu C, Yao X, Ramlee M, Lim M, et al.
Nat Commun
. 2016 Sep;
7:12983.
PMID: 27677335
Regulatory enhancer elements in solid tumours remain poorly characterized. Here we apply micro-scale chromatin profiling to survey the distal enhancer landscape of primary gastric adenocarcinoma (GC), a leading cause of...
2.
Liu C, Ma D, Yan T, Fan X, Poon Z, Poon L, et al.
Stem Cells
. 2016 Jun;
34(10):2471-2484.
PMID: 27299710
In most human somatic cells, the lack of telomerase activity results in progressive telomere shortening during each cell division. Eventually, DNA damage responses triggered by critically short telomeres induce an...
3.
Liu C, Gopalakrishnan V, Poon L, Yan T, Li S
Mol Cell Biol
. 2013 Oct;
34(1):57-70.
PMID: 24164896
In budding yeast (Saccharomyces cerevisiae), the cell cycle-dependent telomere elongation by telomerase is controlled by the cyclin-dependent kinase 1 (Cdk1). The telomere length homeostasis is balanced between telomerase-unextendable and telomerase-extendable...
4.
Zhou J, Bi C, Janakakumara J, Liu S, Chng W, Tay K, et al.
Blood
. 2009 Jan;
113(17):4052-62.
PMID: 19144991
To further investigate potential mechanisms of resistance to FLT3 inhibitors, we developed a resistant cell line by long-term culture of MV4-11 cells with ABT-869, designated as MV4-11-R. Gene profiling reveals...
5.
Jasinghe V, Xie Z, Zhou J, Khng J, Poon L, Senthilnathan P, et al.
J Hepatol
. 2008 Oct;
49(6):985-97.
PMID: 18930332
Background/aims: Receptor tyrosine kinase inhibitors (RTKIs) and mTOR inhibitors are potential novel anticancer therapies for HCC. We hypothesized that combination targeted on distinctive signal pathways would provide synergistic therapeutics. Methods:...